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FGF2-induced effects on transcriptome associated
with regeneration competence in adult human
fibroblasts
Olga Kashpur1, David LaPointe2, Sakthikumar Ambady3, Elizabeth F Ryder1 and Tanja Dominko1*
Abstract
Background: Adult human fibroblasts grown in low oxygen and with FGF2 supplementation have the capacity to
tip the healing outcome of skeletal muscle injury – by favoring regeneration response in vivo over scar formation.
Here, we compare the transcriptomes of control adult human dermal fibroblasts and induced regeneration-
competent (iRC) fibroblasts to identify transcriptional changes that may be related to their regeneration
competence.
Results: We identified a unique gene-expression profile that characterizes FGF2-induced iRC fibroblast phenotype.
Significantly differentially expressed genes due to FGF2 treatment were identified and analyzed to determine
overrepresented Gene Ontology terms. Genes belonging to extracellular matrix components, adhesion molecules,
matrix remodelling, cytoskeleton, and cytokines were determined to be affected by FGF2 treatment.
Conclusions: Transcriptome analysis comparing control adult human fibroblasts with FGF2-treated fibroblasts
identified functional groups of genes that reflect transcriptional changes potentially contributing to their
regeneration competence. This comparative transcriptome analysis should contribute new insights into genes that
characterize cells with greater regenerative potential.
Keywords: Transcriptome, Human fibroblasts, Fibroblast growth factor (FGF2), Wound healing, Regeneration
Background
During development, distinct cell phenotype differenti-
ation is guided by finely tuned and orchestrated changes
in transcriptional activity of specific groups of genes that
become gradually activated (lineage-specific), gradually
repressed (stem cell and progenitor cell genes), or whose
activity does not change substantially (housekeeping
genes). Ultimately, analyzing the transcriptome of a cell
type offers an opportunity to broadly identify transcripts
that define it. In addition to these either developmentally
regulated or artificially induced phenotype changes that
are accompanied by distinct transcriptional changes, a
transcriptome of any given cell type can vary substantially
depending on cell cycle [1-3], passage number, and envir-
onmental factors such as oxygen concentration [4],
temperature, and presence of serum [5].
Another important factor that causes transcriptional
changes and is crucial for maintaining a cell phenotype
is growth substrate. For example, maintenance of undif-
ferentiated state of embryonic stem cells is dependent
on favorable substrate, composed of laminin [6-9],
vitronectin [9-12], fibronectin [9], and collagen IV [8].
In addition to chemical composition, physical properties
of substrate also determine cell fate. Roughness and
stiffness of the surfaces have also been shown to affect
developmental plasticity of cells. Smooth and rigid glass
surface supports undifferentiated phenotype, while rough
and soft substrates promote differentiation [13,14].
Lastly, presence of various growth factors in culture
media can have a significant effect on a cell transcrip-
tional activity and consequently its phenotype. FGF2 is
a mesenchyme-derived growth factor that displays
mitogenic, migratory, and morphogenic functions and
is also known to play role in angiogenesis, organ devel-
opment, organ regeneration, and wound healing [15].
Contrary to its predominantly mitogenic effects on
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differentiated cell types, FGF2 is absolutely required for
maintenance of expression of stemness-related genes.
With respect to wound healing, FGF2 has been studied
as a potential therapeutic anti-scarring agent [15-17].
We have previously investigated the effects of the
aforementioned important cell culture conditions, FGF2
and culture surface, on adult human fibroblasts. We have
observed that adult human fibroblasts demonstrated
FGF2- and surface-mediated induction of some en-
dogenous stem cell genes and a capacity to acquire a
more developmentally plastic phenotype. This low level
of activation of stem cell genes was not sufficient for
induction of a phenotypic conversion into a pluripotent
cell phenotype [18]. However, when transplanted into
skeletal muscle injury, adult human fibroblasts grown in
low oxygen and with supplementation of FGF2 had the
capacity to tip the healing outcome of skeletal muscle
injury – by favoring regeneration response in vivo over
scar formation [19]. The wound repair process consists
of several phases, including immediate response to
injury, inflammatory response, cell proliferation and
migration, ECM contraction, and ECM remodeling. The
roles of dermal fibroblasts in wound healing have been
described [20] and in mammals fibroblasts facilitate col-
lagen deposition and formation of a scar. The cascade
of molecular events leading to scar formation involves
increased proliferation and migration of fibroblasts in
response to growth factors [21], production and
organization of specific ECM components [22,23], and
acquisition of an actin-dependent contractile phenotype
[24]. The wound repair process is complete by forma-
tion of a scar (disorganized extracellular matrix, mainly
collagen) [20].
In this study, we compared transcriptomes of control
fibroblasts and regeneration- competent fibroblasts to
determine whether transcriptional profile that character-
izes regeneration-competent cells reflects disregulation
of genes involved in the default wound healing pathway
leading to scar formation – turning the cells into a more
pro-regenerative phenotype.
Results
The effect of cell growth surface and FGF2 on fibroblast
transcriptome
To obtain a sense of the effects of surface and FGF2
treatment on global transcription, two independent
samples (in three technical replicates each) of human
dermal fibroblasts grown on glass, glass with FGF2,
plastic, and plastic with FGF2 were hybridized to the
Human Whole Genome OneArray® microarray, which con-
tains 29,187 human oligonucleotide probes. Background-
corrected intensity data was normalized and filtered, which
identified 11,124 probes of detectable level of intensity
(Additional file 1). The gene expression dataset is of
excellent quality as indicated by Pearson’s correlation coef-
ficients for biological replicates: 0.987 for glass, 0.973 for
glass with FGF2, 0.960 for plastic, and 0.971 for plastic
with FGF2 (Additional file 2). To investigate cell culture
effects, we examined significantly differentially expressed
gene probes using moderated t-statistic and based on the
false discovery rate (FDR) cutoff value of 0.05. Compari-
son of transcriptomes between cells grown on glass and
plastic in the absence of FGF2 did not identify any differ-
entially expressed genes. However, FGF2-induced changes
in gene expression depended on surface.
FGF2 had a more prominent effect on cells when grown
on plastic than on glass, as determined by the overall
increased number of differentially expressed gene probes
(3,349 on plastic versus 2,185 on glass) (Figure 1A). In
response to FGF2 treatment, 2,012 differentially expressed
gene probes (1,767 genes) were identified that were
disregulated on both surfaces: 1,209 common gene probes
were upregulated (1,071 genes) (Figure 1B) and 803 com-
mon gene probes downregulated (696 genes) (Figure 1C).
In addition to these common genes, FGF2 treatment
disregulated 173 unique gene probes (168 genes: 139
upregulated and 29 downregulated) on glass and 1,337
unique gene probes (1,282 genes: 753 upregulated and 529
downregulated) on plastic (Figure 1). The complete list of
differentially expressed gene probes on glass and on plastic
can be found in Additional file 3 and Additional file 4, re-
spectively. The top 50 significantly differentially expressed
genes are represented in the heat maps (Figure 2A and B,
respectively). All further analyses were performed on
genes whose expression was disregulated in cells grown in
the presence of FGF2 on plastic.
Gene ontology analysis
Differentially expressed genes were analyzed for functional
enrichment. To determine the functions of the genes
affected by FGF2 treatment and consequently identify the
cellular processes that are affected by these transcriptional
changes, we performed Gene Ontology (GO) analysis.
First, all significantly differentially expressed genes were
analyzed to determine broad GO term overrepresentation
using GO slim analysis. GO slim analysis identified broad
terms describing biological processes (Figure 3A), molecu-
lar functions (Figure 3B), as well as cellular components
to which they belong (Figure 3C). Additional file 5 in-
cludes the number of gene probes representing each
GO slim term. A total of 664 overrepresented GO terms
(p < 0.05) associated with biological processes were
identified. These included genes involved in regulation
of cell cycle, cardiovascular system development, extra-
cellular matrix organization, cell proliferation, cell
adhesion, regulation of angiogenesis, cell migration, and
wound healing. Seventy seven overrepresented GO terms
(p < 0.05) were associated with molecular function. The
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genes belonged to extracellular matrix structural constitu-
ents, genes regulating collagen, heparin, integrin binding,
and genes regulating cytokine activity. Sixty five overrepre-
sented GO terms (p < 0.05) were associated with cellular
components and belonged primarily to extracellular com-
ponents (Additional file 6).
Expression of genes associated with wound healing
As FGF2-treated human dermal fibroblasts were previ-
ously shown to participate in wound healing of volu-
metric skeletal muscle by contributing directly to the
pool of satellite PAX7 positive cells and by stimulating
regeneration of endogenous skeletal muscle tissue [19],
we focused further analysis of differentially expressed
genes to those that play a role in wound healing and
could be uniquely identifying regeneration-competent
fibroblasts.
Overall, select genes belonging to extracellular matrix
and its remodeling, inflammation, cytoskeleton and
migration, and growth factor signaling were found to
be affected by FGF2.
Extracellular matrix, matrix remodeling enzymes, and
adhesion molecules
FGF2 treatment led to downregulation of most colla-
gens (COL11A1, COL4A2, COL8A1, COL5A1, COL1A1,
COL12A1, COL15A1) and fibronectin (FN1) and to
upregulation of several laminins (LAMB1, LAMB3,
LAMA3). FGF2 increased expression of select metallo-
peptidases (stromelysines MMP3, MMP10, and MMP11;
MMP1; ADAMTS8), and metallopeptidase inhibitor
TIMP4. Among downregulated genes were TIMP3, and
several other ADAMTS proteinases (ADAMTS5 and
ADAMTS1). Different members of integrin family
responded by significant upregulation (ITGA2, ITGA10,
ITGB3) or downregulation (ITGA11, ITGB2). Signifi-
cantly disregulated genes identified by the microarray
are presented in Table 1. Expression levels of select
target genes identified by the microarray (Figure 4A)
were examined by qRT-PCR (Figure 4B).
Cytoskeleton
Another group of genes found to be regulated by FGF2
treatment were components of the cytoskeleton that are
also involved in wound healing (Table 2). The most
significant effect was observed on ACTC1 and ACTG2.
Expression levels of ACTC1 and ACTG2 identified by
the microarray (Figure 5A) were examined by qRT-PCR
(Figure 5B).
Cytokines, their receptors, and downstream signaling
molecules
Cytokines that were identified to be differentially
expressed are listed in Table 3. FGF2-induced transcrip-
tional increase was observed in genes associated with
inflammation (CXCL1, CXCL5, PTGS2), and growth
factor signaling (EGFR, HGF, MAPK1). Expression of
pro-inflammatory cytokines interleukin-1B (IL1B) and
IL6 decreased upon FGF2 treatment. Signal transducer
and activator of transcription 3 (STAT3), which is a known
downstream target of IL6 signaling, was downregulated
as well as was another downstream IL6/STAT3 gene,
CC chemokine ligand CCL2. Expression levels of all
these targets identified by the microarray (Figure 5A)
were confirmed by qRT-PCR (Figure 5B). FGF2 effect
on expression of TGFB pathway genes included increase
Figure 1 FGF2 changes gene expression in human fibroblasts. A. Venn diagram showing the overlap between differentially expressed gene
probes on plastic and glass. B. Venn diagram depicting the overlap between upregulated gene probes on plastic and glass. C. Venn diagram
depicting the overlap between downregulated gene probes on plastic and glass.
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Figure 2 Top 50 differentially expressed genes due to FGF2 treatment. A. Heat map showing level of gene expression on glass. B. Heat
map showing level of gene expression on plastic.
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in TGFBR3 expression, decrease in TGFBR1, and decrease
in TGFBI (Table 3). TGFB1 and TGFB3 were not signifi-
cantly differentially expressed due to FGF2 treatment.
qRT-PCR results for TGFB1 and TGFBR1 are presented
in Figure 5B.
Discussion
The comparative transcriptome analysis described here
demonstrates a unique molecular signature for induced
regeneration-competent (iRC) fibroblasts compared with
control fibroblasts. Consistent with the notion that these
two cell types are distinctly different, we have used both
cell types in in vivo regeneration experiments and dem-
onstrated that the induced regeneration-competent fi-
broblasts participate in regenerative response of skeletal
muscle (concomitant with decreased scar formation),
contribute to the pool of newly established satellite cells
(PAX7+ cells) in a mouse injury model, as well as form
mature myotubes [19].
Identification of significantly differentially expressed
genes and subsequent Gene Ontology analysis determined
that a large number of genes important for the outcome
Figure 3 GO terms characterizing FGF-affected genes. A. Terms associated with biological process. B. Terms associated with molecular
function. C. Terms associated with cellular component.
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Table 1 ECM, adhesion, and matrix remodeling genes affected by FGF2 treatment
Symbol Name Log2
fold change
Fold change Adjusted
p-value
ECM
Collagens
COL21A1 Collagen, type XXI, alpha 1 2.99 7.97 4.40E-06
COL14A1 Collagen, type XIV, alpha 1 2.25 4.74 3.58E-05
COL13A1 Collagen, type XIII, alpha 1 1.62 3.07 0.003150228
COL18A1 Collagen, type XVIII, alpha 1 1.40 2.64 0.026150843
COL6A3 Collagen, type VI, alpha 3 1.02 2.02 0.026527481
COL10A1 Collagen, type X, alpha 1 0.61 1.52 0.033185205
COL27A1 Collagen, type XXVII, alpha 1 −0.59 −1.50 0.000481652
COL16A1 Collagen, type XVI, alpha 1 −0.86 −1.82 0.000501675
COL1A2 Collagen, type I, alpha 2 −0.92 −1.90 0.001062514
COL12A1 Collagen, type XII, alpha 1 −1.16 −2.23 0.001285122
COL5A1 Collagen, type V, alpha 1 −1.17 −2.25 0.000370081
COL1A1 Collagen, type I, alpha 1 −1.26 −2.40 2.50E-05
COL15A1 Collagen, type XV, alpha 1 −1.40 −2.64 6.04E-06
COL8A1 Collagen, type VIII, alpha 1 −1.92 −3.77 5.23E-08
COL5A2 Collagen, type V, alpha 2 −1.99 −3.96 0.000570978
COL5A3 Collagen, type V, alpha 3 −2.24 −4.72 8.97E-06
COL4A4 Collagen, type IV, alpha 4 −2.34 −5.07 0.001283892
COL4A2 Collagen, type IV, alpha 2 −2.40 −5.28 3.02E-14
COL11A1 Collagen, type XI, alpha 1 −4.27 −19.37 4.50E-12
COL4A1 Collagen, type IV, alpha 1 −4.61 −24.43 3.58E-05
Laminins
LAMA5 Laminin, alpha 5 1.74 3.35 5.24E-06
LAMB1 Laminin, beta 1 0.68 1.60 0.026626565
LAMA4 Laminin, alpha 4 0.66 1.58 0.030288975
LAMA3 Laminin, alpha 3 0.62 1.54 0.033413419
LAMC2 Laminin, gamma 2 −0.78 −1.72 0.001416011
LAMA2 Laminin, alpha 2 −0.81 −1.76 0.048073235
LAMB2 Laminin, beta 2 (laminin S) −0.88 −1.84 0.016068977
LAMC1 Laminin, gamma 1 (formerly LAMB2) −1.34 −2.53 8.56E-05
Fibronectins
FNDC4 Fibronectin type III domain containing 4 1.27 2.41 0.000256057
FNDC3A Fibronectin type III domain containing 3A 0.81 1.75 0.036705362
FNDC3B Fibronectin type III domain containing 3B −1.12 −2.17 0.001723239
FN1 Fibronectin 1 −1.14 −2.20 0.00019286
FNDC1 Fibronectin type III domain containing 1 −4.06 −16.64 2.29E-12
Adhesion molecules
Integrins
ITGA2 Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 3.69 12.92 4.74E-06
ITGA10 Integrin, alpha 10 2.62 6.14 3.90E-07
ITGB3 Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 2.37 5.16 8.55E-05
ITGB1 Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2,
MSK12)
−1.66 −3.15 6.42E-06
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of wound healing such as extracellular matrix genes, adhe-
sion molecules, matrix remodeling genes, and genes in-
volved in inflammation were regulated by FGF2 (Figure 3).
During dermal wound healing, fibroblasts are respon-
sible for ECM production [17] and, here, we show that
FGF2 treatment affects a number of genes involved in
production and remodeling of ECM. FGF2 caused
downregulation of a number of collagens such as colla-
gen IV, collagen XI, collagen V, and collagen I, as well as
caused upregulation of collagen XXI and collagen XIV
(Table 1). qRT-PCR analysis confirmed downregulation
of COL1A1, COL4A1, COL4A2, COL4A4, COL8A1,
and COL11A1 (Figure 4B). FGF2 was previously shown
to downregulate expression of interstitial collagen I and
III [16]. Collagen I is a major component of ECM in
skin, and during wound healing is the main scar
forming collagen. Collagen IV is a major constituent of
basement membrane (other components include laminin,
nidogen, and heparan sulfate proteoglycan perlecan) and
is a predominant type of collagen found in skeletal muscle.
Other ECM genes affected by FGF2 treatment included
laminins and fibronectins (Table 1). Most profoundly
affected by FGF2 treatment were laminin gamma 1
(LAMC1) and laminin alpha 5 (LAMA5). qRT-PCR
confirmed increased expression levels of these two
laminins (Figure 4B). Fibronectin 1 was downregulated
by FGF2 treatment (Figure 4B). FGF2 treatment of hu-
man fibroblasts modulates production of the ECM.
The ECM composition of the FGF2-treated fibroblasts
favors the pro-regenerative outcome in the wound site
directly by affecting the balance between scar forma-
tion and tissue regeneration and potentially thorough
changes in cell attachment to ECM, cell migration, and
cell proliferation.
Cell attachment to the ECM is regulated through
integrins, heterodimers that recognize specific sub-
strates. Adhesion and migration on collagen substrate
is performed through α1β1 and α2β1 and formation of
Table 1 ECM, adhesion, and matrix remodeling genes affected by FGF2 treatment (Continued)
ITGBL1 Integrin, beta-like 1 (with EGF-like repeat domains) −2.31 −4.97 6.78E-08
ITGB2 Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) −3.34 −10.15 0.000457236
Cadherins
CDHR3 Cadherin-related family member 3 1.22 2.33 0.008261441
PCDHGC3 Protocadherin gamma subfamily C, 3 1.21 2.32 0.007298787
PCDH9 Protocadherin 9 1.19 2.29 0.001804197
PCDH10 Protocadherin 10 1.08 2.11 0.00089387
CDH11 Cadherin 11, type 2, OB-cadherin (osteoblast) −0.72 −1.64 0.025796984
PCDHB2 Protocadherin beta 2 −0.76 −1.69 0.010987526
CDH2 Cadherin 2, type 1, N-cadherin (neuronal) −2.05 −4.14 1.11E-05
PCDH7 Protocadherin 7 −2.36 −5.12 0.002357001
Matrix remodeling
MMP1 Matrix metallopeptidase 1 (interstitial collagenase) 4.37 20.61 8.28E-12
ADAMTS8 ADAM metallopeptidase with thrombospondin type 1 motif, 8 3.31 9.94 1.65E-10
MMP27 Matrix metallopeptidase 27 1.90 3.72 4.70E-06
MMP10 Matrix metallopeptidase 10 (stromelysin 2) 1.81 3.52 0.000118221
MMP3 Matrix metallopeptidase 3 (stromelysin 1, progelatinase) 1.81 3.51 7.05E-06
TIMP4 TIMP metallopeptidase inhibitor 4 1.53 2.88 0.000259942
ADAM15 ADAM metallopeptidase domain 15 1.04 2.06 0.000703266
ADAMTSL4 ADAMTS-like 4 0.83 1.77 0.040463485
MMP11 Matrix metallopeptidase 11 (stromelysin 3) 0.82 1.76 0.009142377
ADAMTSL1 ADAMTS-like 1 0.68 1.60 0.024404628
THBS2 Thrombospondin 2 −0.60 −1.52 0.033809806
ADAM19 ADAM metallopeptidase domain 19 −0.82 −1.77 0.016522395
TIMP3 TIMP metallopeptidase inhibitor 3 −1.48 −2.78 8.49E-06
ADAM12 ADAM metallopeptidase domain 12 −2.72 −2.23 1.30E-08
ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 −3.06 −8.32 4.12E-08
ADAMTS5 ADAM metallopeptidase with thrombospondin type 1 motif, 5 −3.99 −15.84 0.000108412
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collagen type I and type III network is dependent on fi-
bronectin and α2β1 [25-27]. We show FGF2-induced
upregulation of β1 and α2 (Figure 4B). Integrins α5β1,
αVβ3, and α4β1 pairs are utilized to bind fibronectin
matrix [28,29], αVβ5 is used to adhere to vitronectin,
and α6β1, α2β1, α3β1 to adhere to laminin and entactin
[10,12,30]. FGF2 treatment downregulated ITGB2 and
upregulated ITGB3 and ITGA10 (Figure 4B). Integrins
connect ECM to actin cytoskeleton via focal adhesions
rich in talin, which is recruited to F-actin, and binds
integrin pairs, which in turn leads to transmission of
F-actin movements to ECM [29]. Change in the com-
position of integrins, as well as in the components of
focal adhesions leads to change in migration, as well as
preferential binding to specific substrate, production
of which is regulated by FGF2 treatment, and may
benefit a pro-regenerative response.
During wound healing, fibroblasts acquire a highly
migratory phenotype. The process is driven by actin
polymerization and resulting microfilaments of the
cell’s leading edge link to ECM via integrins. Acto-
myosin contraction then allows for the disassembly of
adhesions in the rear and movement forward [31].
Thus, movement of the fibroblasts in the wound site is
regulated not only by the ECM and adhesion molecules,
but also by the actin cytoskeleton. Actin cytoskeleton is
also involved in fibroblast contractile phenotype. During
dermis healing, fibroblasts generate stress fibers (weakly
contractile actin bundles) to enable contraction [22].
Fibroblasts’ shape is regulated by the environment and
cell-matrix adhesion determines the cell shape, such as
strong cell-ECM adhesion promotes spindle-shaped
fibroblast [32]. In vitro fibroblasts were shown to have
different morphology depending on the substrate they
Table 2 Cytoskeleton genes regulated by FGF2 treatment
Symbol Name Log2 fold change Fold change Adjusted p-value
TUBA4A Tubulin, alpha 4a 1.29 2.44 0.000256991
TUBB3 Tubulin, beta 3 class III 1.14 2.20 0.00119515
TUBA1C Tubulin, alpha 1c 0.95 1.93 0.002708545
TUBB2C Tubulin, beta 2c 0.60 1.52 0.020192536
ACTA2 Actin, alpha 2, smooth muscle, aorta −0.86 −1.81 0.00445901
ACTN1 Actinin −1.38 −2.60 1.90E-05
TUBE1 Tubulin, epsilon 1 −1.42 −2.68 0.000182139
TUBG2 Tubulin, gamma 2 −2.71 −6.53 0.000159057
ACTC1 Actin, alpha, cardiac muscle 1 −4.38 −20.83 4.46E-11
ACTG2 Actin, gamma 2, smooth muscle, enteric −6.01 −64.33 1.52E-13
Figure 4 FGF2 affects expression levels of genes associated with extracellular matrix remodelling. A. Heat map showing expression levels
of select genes as identified by microarray analysis. B. qRT-PCR validation of microarray data for select genes. Expression levels were normalized
to ACTB and are represented as log2 Fold Change (FGF2-treated compared to untreated). Error bars represent SEM. qRT-PCR for COL1A2 did not
show change in the expression levels.
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are grown on; in 3D cultures resembling an in vivo
environment, fibroblasts display elongated shape, well-
developed actin cortex, and filopodia at the leading
edge [33]. Alpha actin ACTC1, which is a constituent
of the contractile apparatus, was downregulated in
human dermal fibroblasts treated with FGF2 (Table 2;
Figure 5B). Gamma actin ACTG2, which is involved in
cellular motility and adhesion, was 64-fold downregulated
(Table 2), though qRT-PCR did not confirm its expression.
By regulating cytoskeleton gene expression, FGF2 po-
tentially promotes cell migration in the wound site,
and reduces contraction that leads to the favorable
pro-regenerative outcome.
Previously, it was shown that administration of FGF2
alone into a dermal wound shows reduced scar formation
[15], which can be attributed to upregulation of matrix
metalloproteinase MMP1 [17]. Our data shows strong
upregulation of MMP1 (Figure 4B), the metalloproteinase
Figure 5 FGF2 affects expression levels of cytoskeleton genes and chemokines. A. Heat map showing expression levels of select genes as
identified by microarray analysis. B. qRT-PCR validation of microarray data for select genes. Expression levels were normalized to ACTB and are
represented as log2 Fold change (FGF2-treated compared to untreated). Error bars represent SEM. qRT-PCR for IL1B, ACTG2, and TGBR3 did not
show change in the expression levels.
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Table 3 Representative cytokines regulated by FGF2
Symbol Name Log2
fold change
Fold change Adjusted
p-value
Chemokines
CXCL5 Chemokine (C-X-C motif) ligand 5 4.58 16.78 9.18E-07
CXCL6 Chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2) 2.50 5.64 1.23E-07
CXCL1 Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 2.06 4.17 1.59E-05
CCL22 Chemokine (C-C motif) ligand 22 1.55 2.93 0.033547076
C5 Complement component 5 0.88 1.85 0.001196477
CCL26 Chemokine (C-C motif) ligand 26 −0.67 −1.59 0.027966918
CCL14 Chemokine (C-C motif) ligand 14 −1.15 −2.22 0.000191918
CCL25 Chemokine (C-C motif) ligand 25 −1.23 −2.35 0.007193543
CCL2 Chemokine (C-C motif) ligand 2 −1.79 −3.46 6.20E-06
Chemokine receptors
CCRL1 Chemokine (C-C motif) receptor-like 1 2.02 4.06 1.37E-05
CCR10 Chemokine (C-C motif) receptor 10 0.98 1.97 0.043411565
CCR8 Chemokine (C-C motif) receptor 8 −0.58 −1.49 0.047496414
CXCR7 Chemokine (C-X-C motif) receptor 7 −2.26 −4.79 1.24E-06
Interleukins
IL8 Interleukin 8 1.47 2.77 0.013242716
IL17D Interleukin 17D 1.41 2.66 0.000124442
IL1RN Interleukin 1 receptor antagonist 1.18 2.27 0.007602993
IL1B Interleukin 1, beta −1.10 −2.14 0.002340469
IL2 Interleukin 2 −1.19 −2.28 0.034673096
IL32 Interleukin 32 −1.19 −2.28 0.000974257
IL1RAP Interleukin 1 receptor accessory protein −1.91 −3.76 8.85E-06
IL33 Interleukin 33 −2.59 −6.02 0.000613327
IL6 Interleukin 6 (interferon, beta 2) −5.07 −33.59 2.75E-07
Interleukin receptors
IL17RD Interleukin 17 receptor D 2.24 4.72 0.00026435
IL13RA2 Interleukin 13 receptor, alpha 2 1.84 3.58 3.65E-05
IL15RA Interleukin 15 receptor, alpha 0.71 1.64 0.015033555
IL21R Interleukin 21 receptor −0.86 −1.82 0.004974339
IL20RB Interleukin 20 receptor beta −1.29 −2.45 0.000238276
IL1RL1 Interleukin 1 receptor-like 1 −1.99 −3.97 0.002708422
STAT
STAT4 Signal transducer and activator of transcription 4 −1.51 −2.85 1.15E-06
STAT1 Signal transducer and activator of transcription 1 −0.87 −1.83 0.006745
STAT3 Signal transducer and activator of transcription 3 (acute-phase response factor) −0.87 −1.83 0.021783
Tumor necrosis factor family
TNFAIP8L1 Tumor necrosis factor, alpha-induced protein 8-like 1 3.90 14.93 8.62E-07
TNFRSF25 Tumor necrosis factor receptor superfamily, member 25 1.89 3.71 0.000432746
TNFSF10 Tumor necrosis factor (ligand) superfamily, member 10 1.74 3.34 0.005536998
TNFAIP8L3 Tumor necrosis factor, alpha-induced protein 8-like 3 1.31 2.48 9.01E-05
TNFRSF1B Tumor necrosis factor receptor superfamily, member 1B 1.20 2.30 0.027881915
TNFRSF21 Tumor necrosis factor receptor superfamily, member 21 0.67 1.59 0.029823686
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responsible for cleaving collagen type I, II, and III [34].
FGF2 signaling was shown to activate the MMP1 pro-
moter [35]. MMP1 was able to improve the skeletal
muscle regeneration process by reducing scar tissue for-
mation [36-38] and by promoting migration of myoblasts
involved in regeneration of skeletal muscle [39,40]. Inter-
estingly, integrin α2β1 was shown to increase MMP1 ex-
pression [41,42]. By transplanting FGF2 treated human
dermal fibroblasts, continuous increase in production of
MMP1 among other factors, may be allowed, indicating
that MMP1 is present not only at the time of the
resolution phase of wound healing leading to decreased
collagen production, but also at earlier stages of wound
healing, for example during the inflammation stage. Other
MMP molecules, such as stromelysins MMP3, MMP10,
MMP11, were upregulated as well (Table 1 and Figure 4).
MMP3 was previously shown to be responsible for con-
traction of fibroblasts during wound healing [43] and was
regulated by FGF2 in a mouse model [44]. MMPs, mostly
MMP2, 3, 9 and 10, are highly upregulated during
amphibian limb regeneration [45-47]. All of these
observations point toward a favorable role of MMPs
in the regeneration process. Thus, FGF2-stimulated
change in transcriptional profile of various MMPs is
an important factor contributing to the regeneration-
competence of fibroblasts.
FGF2 treatment also led to a favorable ratio between
MMPs and tissue inhibitors of metalloproteinases
(TIMPs), as an imbalance between MMPs and TIMPs
has been shown to increase scar formation. FGF2
upregulated TIMP4 and downregulated TIMP3 expres-
sion (Figure 4B). ADAM and ADAMTS proteinases
that were shown to be differentially regulated by FGF2
(Table 1) are regulators of ECM and adhesion molecules
and affect cell motility, adhesion, and signaling during
wound healing processes. ADAMTS1 and ADAMTS5
were downregulated by FGF2 treatment (Figure 4B).
ADAM transmembrane proteinases are involved in
cleaving and activating various cell surface molecules,
whereas ADAMTS are secreted proteinases that can
bind ECM. ADMATS8 that was upregulated by FGF2
treatment (Figure 4B) has anti-angiogenic properties [48].
The ratio of TGFB1/TGFB3 is a factor that predicts
scar formation, the decrease in this ratio being indicative
of reduced scar formation [11]. Fetal wounds that are
known to heal without scar formation exhibit decreased
TGFB1 levels [49]. Administration of TGFB3 has also
been shown to reduce scar formation [15]. TGFB path-
way was previously shown to be induced by FGF2 treat-
ment in mouse embryonic fibroblasts (MEFs) [50]. We
observed no change in the levels of TGFB1 due to FGF2
treatment by microarray analysis whereas qRT-PCR
showed downregulation of TGFB1 levels (Figure 5B).
We observed upregulation of TGFBR3 due to FGF2
treatment by the array, but qRT-PCR showed no change
in expression levels (Figure 5B). qRT-PCR confirmed
downregulation of TGFBR1 (Figure 5B). These observa-
tions may be due to differences between mouse embryonic
fibroblasts and adult human dermal fibroblasts, indicating
that FGF2 response in these cells may be unique.
Decreasing inflammation has been shown to decrease
scar formation. For example, when wounds of skin and
oral mucosa were compared, there was less inflammation
and scarring in oral mucosa [51]. Non-scar wound healing
in fetal wounds is also characterized by absence of inflam-
mation [52-56]. Inflammatory events are integrated by
chemokines. Chemokines are chemotactic cytokines that
regulate migration of cells during inflammatory process.
Table 3 Representative cytokines regulated by FGF2 (Continued)
C1QTNF6 C1q and tumor necrosis factor related protein 6 −0.70 −1.62 0.035969462
TNFRSF10B Tumor necrosis factor receptor superfamily, member 10b −0.75 −1.68 0.025993715
C1QTNF3 C1q and tumor necrosis factor related protein 3 −0.81 −1.75 0.013142151
TNFAIP6 Tumor necrosis factor, alpha-induced protein 6 −0.85 −1.80 0.021930255
TNFAIP1 Tumor necrosis factor, alpha-induced protein 1 (endothelial) −0.87 −1.83 0.002670969
TNFRSF10D Tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death
domain
−1.14 −2.20 0.003564267
TNFRSF11B Tumor necrosis factor receptor superfamily, member 11b −1.59 −3.01 4.04E-05
C1QTNF5|
MFRP
Membrane frizzled-related protein, C1q and tumor necrosis factor related protein 5
transcription unit
−2.42 −5.35 5.17E-10
TNFSF4 Tumor necrosis factor (ligand) superfamily, member 4 −2.83 −7.11 4.13E-09
TGFΒ pathway
TGFBR3 Transforming growth factor, beta receptor 3 0.94 1.92 0.001259518
TGFBI Transforming growth factor, beta-induced, 68kDa −0.66 −1.58 0.014441976
TGFBR1 Transforming growth factor, beta receptor 1 −0.96 −1.91 0.005746781
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ELR(+) CXC chemokines are neutrophil attractants and
activators. CXCL6 or granulocyte chemotactic protein-2
(GCP-2) is a ELR(+) CXC chemokine. FGF2 treatment led
to increase in CXCL6 chemokine expression (Figure 5B).
CXCL5, a chemokine that attracts and activates neutro-
phils, amplifies inflammatory cascade, and stimulates local
production of cytokines was shown to be upregulated by
FGF2 treatment (Figure 5B). Interestingly, when CXCL5 is
cleaved by MMP1, 2, 8, 9, and 13, increased inflammation
is observed and cell recruitment to the wound site is acti-
vated [57]. CCL2 (monocyte chemoattractant protein-1,
MCP-1), which is involved in inflammatory cell recruit-
ment, can be induced through focal adhesion kinase
(FAK) leading to inflammation and scar production in a
cutaneous injury, and CCL2 knock-out mice showed de-
creased scarring [58]. Here, we observed downregulation
of CCL2 due to FGF2 treatment (Figure 5B). In agreement
with previous publications, implantation of FGF2 treated
fibroblasts, which show CCL2 downregulation, into a
mouse wound sight leads to reduced scar formation [19].
We also show in this transcriptome analysis that IL6/
STAT3 signaling pathway is regulated by FGF2 (Figure 5B).
Interleukin 6 (IL6) is a pleiotropic cytokine that is pro-
duced by a variety of cells such as epidermal cells, endo-
thelial cells, and fibroblasts [59]. IL6 is known to increase
production of collagen [60], thus the decrease in collagen
synthesis that we observe in skeletal muscle injury, can be
partially explained by decrease in IL6. CCL2 was shown to
induce IL6 secretion in human lung fibroblasts, and has a
role in regulating fibrosis [61] and was shown previ-
ously to be regulated by FGF2 [62]. Scarless, fetal
wounds are characterized by diminished expression of
pro-inflammatory IL6 and IL8 [52,53]. Here, we show
that FGF2 treatment significantly reduces IL6 levels
(Figure 5B), whereas levels of IL8 are upregulated with
FGF2 treatment (Table 3). FGF2-induced decrease in
IL6 level could be contributing to pro-regenerative
phenotype of adult human fibroblasts. Signal transducer
and activator of transcription (STAT3) conveys signals
from IL6. Loss of IL6 was shown to result in deficiency
of proliferation and migration of myoblasts [63-65].
IL6/STAT3 was shown recently to be involved in exces-
sive ECM production and increased cellular prolifera-
tion in hypertrophic scars compared to normal human
fibroblasts [66].
Conclusions
Comparison of transcriptomes between control and
regeneration-competent fibroblasts indicates significant
differences in expression of genes involved in several
biological processes during wound healing. Downregulation
of collagens, upregulation of ECM remodeling enzymes,
and downregulation of pro-inflammatory cytokines may
be in part responsible for the cells’ pro-regenerative
phenotype. A choice between scar-forming and pro-
regenerative wound healing responses may depend on a
balance between ECM production, degradation, conse-
quent ECM contractility, and decreased inflammatory re-
sponse. Further studies are needed to elucidate functional
significance of specific disregulated genes.
Methods
Cell culture
Adult human dermal fibroblasts were obtained from
ATCC (CRL-2352) at passage number 1 (p1). Cells were
expanded using culture conditions recommended by the
supplier, namely ambient oxygen, 5% CO2 in air, 37°C in
DMEM/F12 and 10% FBS. Expansion was done by
trypsinizing (0.05% trypsin, Cellgro) the cells at 80% con-
fluence and replating them at a density of 14,000 cells/cm2.
Cells were cryopreserved with DMSO and the same
passage used for all the experimental groups. Cells from
the same passage number 7 were grown for seven days
at 5% O2, 5% CO2, 37°C in DMEM/F12 and 10% FCIII in
one of the following culture conditions: 1. with 4 ng/ml
human recombinant FGF2 (PeproTech) on tissue culture
plastic; 2. with 4 ng/ml human recombinant FGF2 on glass
culture surface; 3. on tissue culture plastic; and 4. on glass
culture surface. After 7 days, cells were used for three
RNA collections for transcriptome arrays and qRT-PCR.
RNA isolation
Total RNA was isolated from all treatment groups using
TRIZOL reagent (Invitrogen) following manufacturer’s
protocol.
OneArray microarray sample and data processing
To obtain a sense of global effects of surface and FGF2,
two independent samples (in three technical replicates
each) of cells grown on glass, glass with FGF2, plastic,
and plastic with FGF2 were hybridized to the Human
Whole Genome OneArray® v5 (Phalanx Biotech, Palo Alto,
CA). RNA quality and integrity were determined utilizing
an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo
Alto, CA, USA) and absorbance at A260/A280. Only high
quality RNA, having a RIN of >7.0, and an A260/280
absorbance ratio of >1.8, was utilized for further experi-
mentation. RNA was converted to double-stranded
cDNA and amplified using in vitro transcription that
included amino-allyl UTP, and the aRNA product was
subsequently conjugated with Cy5™ NHS ester (GEH
Lifesciences). Fragmented aRNA was hybridized at 50°C
overnight using the HybBag mixing system with 1X
OneArray Hybridization Buffer (Phalanx Biotech),
0.01 mg/ml sheared salmon sperm DNA (Promega,
Madison, WI, USA), at a concentration of 0.025 mg/ml
labeled target. After hybridization, the arrays were washed
according to the OneArray protocol. Raw intensity signals
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for each microarray were captured using a Molecular
Dynamics™ Axon 4100A scanner, measured using
GenePixPro™ Software, and stored in GPR format.
Data analysis
The data was analyzed with R/bioconductor using
standard statistical functions and analysis modules for
the ANOVA, T test, FDR, and functional analysis [67,68].
Analysis was performed in the following order. First, data
was background corrected, normalized, and filtered to
remove probes with very low expression or low vari-
ance (expression but no variation) across conditions.
Next, 2-way ANOVA was performed to determine signifi-
cant gene probes for the two factors and possible interac-
tions between cell culture surface and FGF2. LIMMA
package was used to determine significantly differentially
expressed genes (DEG) with moderate t-statistic as main
statistic of significance and standard errors moderated
using Bayesian model [69-71]. P-values were adjusted for
multiple comparisons using Benjamini and Hochberg
method to control the false discovery rate (FDR) [72].
FDR cutoff value of 0.05 was used.
Gene Ontology (GO) analysis was performed to analyze
functional enrichment within DEG due to FGF2 treatment
in human dermal fibroblasts cultured on plastic. DEG due
to FGF2 treatment were profiled for GO slim using
geneListPie package [73]. In order to perform GO analysis,
GOstats package was used [74]. Hypergeometric condi-
tional testing was performed to obtain overrepresented
GO terms that belong to three groups: biological process,
molecular function, and cellular component.
Quantitative RT-PCR
cDNA was prepared from total RNA using QuantiTect
Reverse Transcription kit (Qiagen) using mixture of
oligo-dT and random primers method. The kit also
includes elimination of genomic DNA step prior to
reverse transcription. 1 μg of total RNA was used for
cDNA preparation. For each qPCR reaction 20 ng of
cDNA were used. qPCR was performed using SYBR SE-
LECT master mix (Invitrogen). The list of primers can
be found in Additional file 7. Quantification of qPCR
results was performed by the ΔΔCT method.
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